Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity After Single and Multiple Dose Administration of FB102 Administered in Healthy Participants

NCT07623057 is registered in ClinicalTrials.gov with Forte Biosciences, Inc. as lead sponsor.

NCT NCT07623057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07623057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity After Single and Multiple Dose Administration of FB102 Administered in Healthy Participants
Lead sponsor
Forte Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 23, 2026
Completion date
February 28, 2027
Enrollment
48 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer